Physician profile
Bobby George
NPI 1295267144
$5,787.34
in general payments reported to CMS, 2019-2025
23 companies · $1,627 in 2025
The $1,627 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,619 · 2022: $980 · 2023: $346 · 2024: $1,216 · 2025: $1,627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,187.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,797.93 | 2021-2025 | Unid_pass, Mazor X System, O-Arm |
| Globus Medical, INC. | $1,076.16 | 2022-2025 | Sable, Excelsius Deformity, Maxcess |
| Alphatec Spine, INC | $753.59 | 2021 | |
| Ucb, INC. | $344.94 | 2024-2025 | Rystiggo, Fintepla, Briviact |
| Si-Bone, INC. | $271.76 | 2021 | |
| Boston Scientific Corporation | $247.43 | 2022-2025 | Enroute Transcarotid Neuroprotection System |
| Stryker Corporation | $232.61 | 2021-2025 | Sonopet Iq, N/A |
| Integra Lifesciences Corporation | $192.21 | 2022 | |
| Novartis Pharmaceuticals Corporation | $170.03 | 2025 | |
| Abbvie INC. | $124.15 | 2024-2025 | |
| Depuy Synthes Sales INC. | $120.67 | 2022-2023 | Teligen, Symphony |
| Lilly USA, LLC | $81.89 | 2024-2025 | Kisunla, Amyvid, Emgality |
| Genentech USA, INC. | $55.81 | 2025 | Ocrevus Zunovo |
| Silk Road Medical, INC. | $48.25 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Lundbeck LLC | $41.44 | 2024-2025 | Vyepti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $41.05 | 2024-2025 | Vumerity, Tysabri, Skyclarys |
| Azurity Pharmaceuticals, INC. | $35.71 | 2024-2025 | Horizant |
| Neurocrine Biosciences, INC. | $33.69 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.21 | 2025 | Hyqvia |
| Harmony Biosciences LLC | $25.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $25.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $22.97 | 2022 | |
| Amneal Pharmaceuticals LLC | $14.84 | 2025 | Crexont |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bobby George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.